Pimavanserin

Aka: Pimavanserin, Nuplazid

advertisement

II. Indications

  1. Parkinsonism-related Psychosis (Hallucinations, Delusions)

III. Dosing

  1. Start 34 mg orally daily
    1. Lower dose to 10 mg daily if on CYP3A4 Inhibitors

IV. Mechanism

  1. Atypical Antipsychotic
  2. Serotonin 5HT2 Antagonist

V. Drug Interactions

  1. Metabolized by CYP3A4
  2. Avoid with strong CYP3A4 inducers

VI. Adverse Effects

  1. See Antipsychotic Medication
  2. QTc Prolongation

VII. Safety

  1. Unknown safety in pregnancy
  2. Unknown safety in Lactation

VIII. Resources

  1. Pimavanserin (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b

IX. References

  1. (2016) Med Lett Drugs Ther 58(1510): 160-5
  2. Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 42-3
  3. Hamilton (2020) Tarascon Pocket Pharmacopoeia

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Pimavanserin." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Related Topics in Pharmacology

advertisement